News >

NICE Recommends Olaparib Maintenance in Relapsed, Platinum-Sensitive Ovarian Cancer

Kristi Rosa
Published: Wednesday, Jan 15, 2020

The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.1

Olaparib is specifically recommended as a maintenance treatment option for adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy only if they harbor a BRCA1/2 mutation, they received ≥3 courses of platinum-based chemotherapy, and the manufacturer provides the agent according to the commercial arrangement.

Moreover, the PARP inhibitor has also been recommended for use within the Cancers Drugs Fund as a maintenance treatment option in this patient population if they harbor a BRCA1/2 mutation, they previously received 2 courses of platinum-based chemotherapy, and the conditions in the managed access agreement for the PARP inhibitor are followed.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x